M
Miri Sklair-Levy
Researcher at Sheba Medical Center
Publications - 27
Citations - 331
Miri Sklair-Levy is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Breast cancer & Mammography. The author has an hindex of 9, co-authored 27 publications receiving 167 citations.
Papers
More filters
Journal ArticleDOI
COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.
Renata Faermann,Noam Nissan,Osnat Halshtok-Neiman,Anat Shalmon,Michael Gotlieb,Yael Yagil,David Samoocha,Eitan Friedman,Miri Sklair-Levy +8 more
TL;DR: In this article, an increase in axillary-lymphadenopathy attributed to vaccination was found in 163 women undergoing breast-imaging, including BRCA-carriers.
Journal ArticleDOI
Residual Glandular Breast Tissue After Mastectomy: A Systematic Review.
Orit Kaidar-Person,Orit Kaidar-Person,Liesbeth J. Boersma,Philip Poortmans,Miri Sklair-Levy,Birgitte Vrou Offersen,Maria João Cardoso,Dirk De Ruysscher +7 more
TL;DR: The rate of rBGT was reported in up to 100% of the patients and was found to be associated mainly with the type of surgical resection, indication, and surgeon’s expertise.
Journal ArticleDOI
Classification of contrast-enhanced spectral mammography (CESM) images.
TL;DR: A deep learning-based decision support system aimed at improving the specificity of breast cancer diagnosis by CESM without affecting sensitivity, and may significantly reduce benign biopsies, without compromising sensitivity.
Journal ArticleDOI
Challenges in contrast-enhanced spectral mammography interpretation: artefacts lexicon
Yael Yagil,Anat Shalmon,Arie Rundstein,Yael Servadio,Osnat Halshtok,Michael Gotlieb,Miri Sklair-Levy +6 more
TL;DR: Two main artefacts commonly seen on CESM are rim and ripple artefacts, which do not hamper with image interpretation and are important to be aware of and prevent misinterpretation of these artefacts as real breast pathology.
Journal ArticleDOI
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
Dana Madorsky-Feldman,Miri Sklair-Levy,Tamar Perri,Yael Laitman,Shani Paluch-Shimon,Rita K. Schmutzler,Kerstin Rhiem,Jenny Lester,Beth Y. Karlan,Christian F. Singer,Tom Van Maerken,Kathleen Claes,Joan Brunet,Angel Izquierdo,Alex Teulé,Jong Won Lee,Sung-Won Kim,Banu Arun,Anna Jakubowska,Jan Lubinski,Katherine L. Tucker,Nicola K. Poplawski,Nicola K. Poplawski,Liliana Varesco,Luigina Bonelli,Saundra S. Buys,Gillian Mitchell,Marc Tischkowitz,Anne-Marie Gerdes,Caroline Seynaeve,Mark E. Robson,Ava Kwong,Nadine Tung,Nalven Tessa,Susan M. Domchek,Andrew K. Godwin,Johanna Rantala,Brita Arver,Eitan Friedman,Eitan Friedman +39 more
TL;DR: From this comprehensive multinational study it is clear that evidence-based, long-term prospective data on the most effective scheme for BRCA carriers post RRS is needed.